The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Hizentra

200 milligram(s)/millilitre Solution for injection

CSL Behring GmbHEU/1/11/687/001-12

Main Information

Trade NameHizentra
Active SubstancesHuman normal immunoglobulin
Strength200 milligram(s)/millilitre
Dosage FormSolution for injection
Licence HolderCSL Behring GmbH
Licence NumberEU/1/11/687/001-12

Group Information

ATC CodeJ06BA01 immunoglobulins, normal human, for extravascular adm.

Status

Authorised/WithdrawnAuthorised
Licence Issued14/04/2011
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back